Infinity Pharmaceuticals Incorporated (NASDAQ:INFI) Sellers Covered 9.23% of Their Shorts


The stock of Infinity Pharmaceuticals Incorporated (NASDAQ:INFI) registered a decrease of 9.23% in short interest. INFI’s total short interest was 1.76 million shares in September as published by FINRA. Its down 9.23% from 1.94 million shares, reported previously. With 353,000 shares average volume, it will take short sellers 5 days to cover their INFI’s short positions. The short interest to Infinity Pharmaceuticals Incorporated’s float is 4.71%. The stock decreased 4.79% or $0.07 during the last trading session, hitting $1.39. About 288,648 shares traded hands. Infinity Pharmaceuticals Inc. (NASDAQ:INFI) has declined 73.41% since February 8, 2016 and is downtrending. It has underperformed by 89.89% the S&P500.

Infinity Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $70.37 million. The Firm is engaged in the discovery, development and delivery of medicines to treat diseases. It has a 4.8 P/E ratio. The Firm develops small molecule drugs that target disease pathways for potential applications in oncology.

The institutional sentiment decreased to 0.76 in 2016 Q2. Its down 0.35, from 1.11 in 2016Q1. The ratio dived, as 28 funds sold all Infinity Pharmaceuticals Inc. shares owned while 34 reduced positions. 17 funds bought stakes while 30 increased positions. They now own 39.59 million shares or 11.46% less from 44.72 million shares in 2016Q1.

Bvf Inc Il holds 1.47% of its portfolio in Infinity Pharmaceuticals Inc. for 5.18 million shares. Deerfield Management Co owns 1.94 million shares or 0.1% of their US portfolio. Moreover, Globeflex Capital L P has 0.07% invested in the company for 204,399 shares. The New York-based Orbimed Advisors Llc has invested 0.05% in the stock. Oxford Asset Management, a United Kingdom-based fund reported 771,506 shares.

Out of 9 analysts covering Infinity Pharmaceuticals (NASDAQ:INFI), 1 rate it a “Buy”, 0 “Sell”, while 8 “Hold”. This means 11% are positive. Infinity Pharmaceuticals has been the topic of 13 analyst reports since September 21, 2015 according to StockzIntelligence Inc. RBC Capital Markets downgraded the stock on June 15 to “Sector Perform” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply